Mepolizumab proved efficacious for eosinophilic granulomatosis with polyangiitis (EGPA, former Churg-Strauss) at the dosage of 300mg/4 weeks in the randomized controlled MIRRA trial. Few successful real-life experiences with the dosage approved for severe eosinophilic asthma (100mg/4 weeks) were recently reported. We retrospectively assessed the effectiveness and safety of mepolizumab 100 and 300mg/4 weeks in a large European EGPA cohort.
Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study / Bettiol, Alessandra; Urban, Maria Letizia; Dagna, Lorenzo; Cottin, Vincent; Franceschini, Franco; Del Giacco, Stefano; Schiavon, Franco; Neumann, Thomas; Lopalco, Giuseppe; Novikov, Pavel; Baldini, Chiara; Lombardi, Carlo; Berti, Alvise; Alberici, Federico; Folci, Marco; Negrini, Simone; Sinico, Renato Alberto; Quartuccio, Luca; Lunardi, Claudio; Parronchi, Paola; Moosig, Frank; Espígol-Frigolé, Georgina; Schroeder, Jan; Kernder, Anna Luise; Monti, Sara; Silvagni, Ettore; Crimi, Claudia; Cinetto, Francesco; Fraticelli, Paolo; Roccatello, Dario; Vacca, Angelo; Mohammad, Aladdin J; Hellmich, Bernhard; Samson, Maxime; Bargagli, Elena; Cohen Tervaert, Jan Willem; Ribi, Camillo; Fiori, Davide; Bello, Federica; Fagni, Filippo; Moroni, Luca; Ramirez, Giuseppe Alvise; Nasser, Mouhamad; Marvisi, Chiara; Toniati, Paola; Firinu, Davide; Padoan, Roberto; Egan, Allyson; Seeliger, Benjamin; Iannone, Florenzo; Salvarani, Carlo; Jayne, David; Prisco, Domenico; Vaglio, Augusto; Emmi, Giacomo. - In: ARTHRITIS & RHEUMATOLOGY. - ISSN 2326-5191. - 74:2(2022), pp. 295-306. [10.1002/art.41943]
Mepolizumab for Eosinophilic Granulomatosis with Polyangiitis (EGPA): a European multicenter observational study
Marvisi, Chiara;Salvarani, Carlo;
2022
Abstract
Mepolizumab proved efficacious for eosinophilic granulomatosis with polyangiitis (EGPA, former Churg-Strauss) at the dosage of 300mg/4 weeks in the randomized controlled MIRRA trial. Few successful real-life experiences with the dosage approved for severe eosinophilic asthma (100mg/4 weeks) were recently reported. We retrospectively assessed the effectiveness and safety of mepolizumab 100 and 300mg/4 weeks in a large European EGPA cohort.
| File | Dimensione | Formato | |
|---|---|---|---|
|
Arthritis Rheumatology - 2021 - Bettiol - Mepolizumab for Eosinophilic Granulomatosis With Polyangiitis A European.pdf
Open access
Tipologia:
VOR - Versione pubblicata dall'editore
Dimensione
703.81 kB
Formato
Adobe PDF
|
703.81 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
